|
CN111825613A
|
|
Tetrahydroisoquinoline compounds as selective estrogen receptor down-regulation agent, and synthesis method and application thereof
|
|
CN110606860A
|
|
Pyridine sulfonamide phosphate compound, preparation method and application thereof
|
|
CN110372557A
|
|
Hexamethylene amine D3/D2Acceptor portion agonist
|
|
CN110305140A
|
|
Pyrrolin miazines selectivity JAK2 inhibitor
|
|
CN110028509A
|
|
The alternatively azolopyrimidines of property JAK2 inhibitor, its synthetic method and purposes
|
|
CN110054647A
|
|
Torasemide phosphoric acid ester prodrug, preparation method and composition
|
|
CN110606826A
|
|
Torasemide sodium monohydrate, crystal forms and compositions thereof
|
|
CN110003204A
|
|
A kind of BET protein inhibitor, preparation method and the usage
|
|
CN106478504A
|
|
The method preparing Roxadustat intermediate
|
|
CN106478503A
|
|
The preparation method of Roxadustat intermediate
|
|
CN107629071A
|
|
Substitution 2,4（1H,3H）Hybar X is as PARP inhibitor and its application
|
|
CN107629057A
|
|
BET protein inhibitors and its application
|
|
CN107286174A
|
|
Substitution 2,4- (1H, 3H) hybar Xs are used as PARP inhibitor and its application
|
|
CN107286180A
|
|
Miscellaneous generation Pyridopyrimidinone derivatives are used as CDK inhibitor and its application
|
|
CN107286166A
|
|
Replace 1,3,4,5- tetrahydrochysene -6H- pyrrolo-es [4,3,2-EF] [2] benzo-aza -6- ketone derivatives
|
|
CN107286134A
|
|
2,4- disubstituted pyrimidines derivatives are used as CDK inhibitor and its application
|
|
CN105481922A
|
|
Preparation method of cangrelor intermediate
|
|
CN105440026A
|
|
Elopiprazole preparation method
|
